Q-omics provides the consensus-scored CHRNA2 profile across patient tissues and cancer cell-line models. CHRNA2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CHRNA2 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CHRNA2 protein abundance shows 17,264 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LUAD, and GBM as cancer lineages where CHRNA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRNA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRNA2 survival associations across molecular data types. CHRNA2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRNA2 RNA expression–survival associations across cancer types. High CHRNA2 expression shows unfavorable associations in ACC, but favorable associations in BRCA, CESC, HNSC, LGG and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for CHRNA2 RNA expression.
This table summarizes CHRNA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CHRNA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRNA2 shows lower tumor expression in LUAD, LUSC, BRCA, READ, KICH and KIRC. The LUAD box plot shows higher CHRNA2 RNA expression in normal versus tumor tissue (log2 FC = −0.748, t-test p < 0.001).
This table shows molecular features associated with CHRNA2 in patient tissues and cancer cell lines. In patient samples, CHRNA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRNA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
